Headline »
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease
Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Archive by Day

Article Archive for 23 June 2009

Also In Global Health News: Venezuela Voids Pharma Patents; Namibia Sanitation; Mapping Disease With Satellites; Zimbabwe Health Funding
Tuesday, 23 Jun, 2009 – 5:00 | No Comment

Venezuela To Void Some Pharmaceutical Patents Commerce Minister Eduardo Saman on Saturday said Venezuela plans to void some pharmaceutical patents and allow domestic manufacturers to produce licensed …

WorldCare Clinical Implements MCC’s Imaging Performance Metrics In Support Of Standardized Peformance For Imaging Trials
Tuesday, 23 Jun, 2009 – 4:00 | No Comment

45th DIA Annual Meeting — Booth # 1501 — WorldCare Clinical, LLC (WCC), a leading imaging CRO for clinical trials in the pharmaceutical, biotechnology and medical device industries, announced that it is offering version 1.0 …